Form 4: Sarepta Therapeutics CFO Ian Estepan Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Ian Michael Estepan, CFO of Sarepta Therapeutics, reports the sale of 1,370 shares of common stock to cover tax withholding obligations related to vesting of restricted stock units.
Summary
- On March 4, 2025, Ian Michael Estepan, the Chief Financial Officer of Sarepta Therapeutics, sold 1,370 shares of common stock.
- The sale was executed to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 3, 2021.
- The shares were sold at a price of $101.34 per share.
- Following the transaction, Estepan directly owns 44,956 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an executive's stock sale for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This transaction is a common occurrence where executives sell shares to cover tax obligations related to equity compensation.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/03/2021 | Date of grant for restricted stock units related to the tax obligation. |
| 03/04/2025 | Date of the stock sale transaction. |
| 03/06/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.